基于物联网的家庭无创通气用于伴高碳酸血症慢性呼吸衰竭的慢阻肺患者:随机对照试验研究方案
本研究为多中心前瞻性随机对照试验,计划纳入200例伴慢性高碳酸血症性呼吸衰竭的慢阻肺患者,按1:1随机分为常规家庭无创正压通气组和附加物联网管理组,干预12个月。主要结局为严重呼吸功能不全问卷,次要结局包括呼吸机依从性、气体交换、肺功能、健康相关生活质量、住院频率、1年内死亡时间、全因死亡率、安全性和成本效果分析。
要点
- 多中心前瞻性随机对照试验,纳入200例伴高碳酸血症慢性呼吸衰竭的慢阻肺患者,1:1随机分组。
- 干预组在常规家庭无创正压通气基础上附加物联网管理,对照组仅常规通气,干预12个月。
- 主要结局为严重呼吸功能不全问卷,次要结局包括依从性、气体交换、肺功能、生活质量、住院频率、死亡、安全性和成本效果。
核心结论
- 该研究旨在评估基于物联网的家庭无创正压通气管理对伴高碳酸血症慢性呼吸衰竭的慢阻肺患者的有效性和安全性。
- 作者称本研究将是中国首个且规模最大的评估该管理模式的随机试验,结果可能为未来家庭无创正压通气治疗和管理提供新证据。
研究设计与样本
- 多中心、前瞻性、随机对照试验,共纳入200例伴慢性高碳酸血症性呼吸衰竭的慢阻肺患者。
- 采用计算机生成的随机化过程,按1:1比例将患者随机分为常规无创正压通气组(对照组)或附加物联网管理组(干预组),干预12个月。
- 主要结局为严重呼吸功能不全问卷;次要结局包括呼吸机依从性、气体交换、肺功能、健康相关生活质量、住院频率、1年内死亡时间、全因死亡率、安全性分析和成本效果分析。
- 试验注册于中国临床试验注册中心,注册号ChiCTR1800019536,注册日期2018年11月17日。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Home noninvasive positive pressure ventilation (NIPPV) has become evidence-based care for stable hypercapnic chronic obstructive pulmonary disease (COPD) patients. There are still other challenges including appropriate follow-up, telemonitor, and management to ensure treatment effectiveness, compliance, and security and to improve quality of life. The Internet of things (IOT) is the name given to the network of devices and other "things" with built-in sensors, software, electronics, and network connectivity, communicating these objects over wireless networks and sending data to a cloud platform. The study aims to evaluate the effectiveness and safety of the IOT-based management of NIPPV for the COPD patients with hypercapnic chronic respiratory failure. METHODS: This multicenter, prospective, randomized controlled trial was conducted with a total of 200 COPD patients with chronic hypercapnic respiratory failure. Using a computer-generated randomization process, patients were randomized (in a 1:1 ratio) into the usual NIPPV (control group) or to receive additional IOT-based management (intervention group) for 12 months. The primary outcome was the Severe Respiratory Insufficiency (SRI) questionnaire. Secondary outcomes included compliance with the ventilator, gas exchange, lung function, health-related quality of life, hospitalization frequency, time to death within 1-year, all-cause mortality, safety analysis, and cost-effectiveness analysis. DISCUSSION: This study will be the first and largest randomized trial in China to evaluate the effectiveness and safety of the IOT-based management of NIPPV for COPD patients with chronic hypercapnic respiratory failure. The results will help to understand the current situation of IOT-based home ventilation and may provide new evidence for home NIPPV treatment and management in the future. TRIAL REGISTRATION: Chinese Clinical Trials Registry ChiCTR1800019536 . Registered on 17 November 2018.
引用
- Jiang W, Song Y. Internet of things-based home noninvasive ventilation in COPD patients with hypercapnic chronic respiratory failure: study protocol for a randomized controlled trial. Trials. 2022. PMID: 35551646. doi:10.1186/s13063-022-06372-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。